Notice of Intent To Grant Partially Exclusive License, 41455 [E9-19487]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 157 / Monday, August 17, 2009 / Notices
Dated: August 7, 2009.
Lisa J. Lierheimer,
Senior Permit Biologist, Branch of Permits,
Division of Management Authority.
[FR Doc. E9–19579 Filed 8–14–09; 8:45 am]
BILLING CODE 4310–55–P
DEPARTMENT OF JUSTICE
mstockstill on DSKH9S0YB1PROD with NOTICES
Notice of Lodging of Modified Consent
Decree Pursuant to the Clean Air Act
Notice is hereby given that on August
11, 2009, a proposed modified Consent
Decree in United States et al. v. Ohio
Edison Co., et al., (S.D. Ohio), No. C2–
99–1181, was lodged with the United
States District Court for the Southern
District of Ohio. The proposed modified
Decree is incorporated within a Joint
Motion to Modify Consent Decree with
Order Modifying Consent Decree, filed
the same day in the same court.
Under the proposed modified Consent
Decree, Ohio Edison agrees to repower
one of its coal-fired power plants—the
R.E. Burger Generating Station Units 4
and 5 (‘‘Burger’’) near Shadyside,
Ohio—using primarily renewable
biomass fuel. The agreement, joined by
the States of New York, Connecticut and
New Jersey, modifies a 2005 consent
decree requiring reductions in Ohio
Edison’s emissions of sulfur dioxide
(‘‘SO2’’) and nitrogen oxide (‘‘NOX’’).
The modified decree will substantially
reduce emissions of SO2 and NOX from
Burger’s current levels and significantly
reduce net carbon dioxide emissions
from current levels.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the modified Consent Decree.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and either e-mailed to
pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
States et al. v. Ohio Edison, et al., (S.D.
Ohio.), No. C2–99–1181, D.J. Ref. 90–5–
2–1–06894. The modified Consent
Decree may be examined at the Office of
the United States Attorney, Southern
District of Ohio, 280 North High Street,
Fourth Floor, Columbus, Ohio 43215.
During the public comment period, the
modified Consent Decree may also be
examined on the following Department
of Justice Web site, https://
www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
modified Consent Decree may also be
obtained by mail from the Consent
Decree Library, P.O. Box 7611, U.S.
VerDate Nov<24>2008
17:55 Aug 14, 2009
Jkt 217001
Department of Justice, Washington, DC
20044–7611 or by faxing or e-mailing a
request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy from the Consent Decree Library,
please enclose a check in the amount of
$2.50 (25 cents per page reproduction
cost) payable to the U.S. Treasury.
Maureen Katz,
Deputy Chief, Environmental Enforcement
Section.
[FR Doc. E9–19564 Filed 8–14–09; 8:45 am]
BILLING CODE 4410–15–P
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[Notice (09–072)]
Notice of Intent To Grant Partially
Exclusive License
AGENCY: National Aeronautics and
Space Administration.
ACTION: Notice of intent to grant
partially exclusive license.
SUMMARY: This notice is issued in
accordance with 35 U.S.C. 209(c)(1) and
37 CFR 404.7(a)(1)(i). NASA hereby
gives notice of its intent to grant an
exclusive license worldwide to practice
the invention described and claimed in
U.S. Patent No. 7,094,045,
entitled‘‘Microencapsulation System
and Method’’, U.S. Patent No. 7,295,309,
entitled ‘‘Microparticle Analysis System
and Method’’ to NuVue Therapeutics,
Inc. (formerly known as Critical Care
Innovations, Inc.), having its principal
place of business in Fairfax, Virginia.
The fields of use are for both clinical
and veterinary applications in the
production and applications of
microcapsules and microencapsulation
of all cyto-toxic anti-cancer drugs. Also
included are externally-triggered
microcapsules including the use of
ultrasound and magnetic flux triggering
technologies, in situ activation inside
microcapsules, cell encapsulation, and
urokinase and DNA measurement of
metastasis for diagnostic testing. The
patent rights in these inventions have
been assigned to the United States of
America as represented by the
Administrator of the National
Aeronautics and Space Administration.
The prospective partially exclusive
license will comply with the terms and
conditions of 35 U.S.C. 209 and 37 CFR
404.7.
DATES: The prospective partially
exclusive license may be granted unless,
within fifteen (15) days from the date of
this published notice, NASA receives
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
41455
written objections including evidence
and argument that establish that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Competing applications completed and
received by NASA within fifteen (15)
days of the date of this published notice
will also be treated as objections to the
grant of the contemplated exclusive
license.
Objections submitted in response to
this notice will not be made available to
the public for inspection and, to the
extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
ADDRESSES: Objections relating to the
prospective license may be submitted to
Patent Counsel, Office of Chief Counsel,
Mail Code AL, 2101 NASA Parkway,
Houston, TX 77058, (281) 483–4871;
(281) 483–6936 [Facsimile].
FOR FURTHER INFORMATION CONTACT:
Theodore U. Ro, Patent Attorney, Office
of Chief Counsel, Johnson Space Center,
Mail Code AL, 2101 NASA Parkway,
Houston, TX 77058, (281)244–7148;
(281)483–6936 [Facsimile]. Information
about other NASA inventions available
for licensing can be found online at
https://technology.nasa.gov/.
Dated: August 7, 2009.
Richard W. Sherman,
Deputy General Counsel.
[FR Doc. E9–19487 Filed 8–14–09; 8:45 am]
BILLING CODE P
NUCLEAR REGULATORY
COMMISSION
[Docket No.: 70–1151; NRC–2009–0355; EA–
08–244; License No.: SNM–1107]
In the Matter of Westinghouse Electric
Company LLC; Confirmatory Order
(Effective Immediately)
I
Westinghouse Electric Company LLC
(WEC or Licensee) is the holder of
Operating License No. SNM–1107
issued by the Nuclear Regulatory
Commission (NRC or Commission)
pursuant to 10 CFR part 70. The license
in effect at the time of the matters
described below was most recently
amended via Amendment 5, issued on
April 10, 2009. The license authorizes
the operation of WEC in accordance
with the conditions specified therein.
The facility is located on the Licensee’s
site in Columbia, South Carolina.
This Confirmatory Order is the result
of an agreement reached during an
Alternative Dispute Resolution (ADR)
E:\FR\FM\17AUN1.SGM
17AUN1
]]>Agencies
[Federal Register Volume 74, Number 157 (Monday, August 17, 2009)]
[Notices]
[Page 41455]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19487]
=======================================================================
-----------------------------------------------------------------------
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
[Notice (09-072)]
Notice of Intent To Grant Partially Exclusive License
AGENCY: National Aeronautics and Space Administration.
ACTION: Notice of intent to grant partially exclusive license.
-----------------------------------------------------------------------
SUMMARY: This notice is issued in accordance with 35 U.S.C. 209(c)(1)
and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to
grant an exclusive license worldwide to practice the invention
described and claimed in U.S. Patent No. 7,094,045,
entitled``Microencapsulation System and Method'', U.S. Patent No.
7,295,309, entitled ``Microparticle Analysis System and Method'' to
NuVue Therapeutics, Inc. (formerly known as Critical Care Innovations,
Inc.), having its principal place of business in Fairfax, Virginia. The
fields of use are for both clinical and veterinary applications in the
production and applications of microcapsules and microencapsulation of
all cyto-toxic anti-cancer drugs. Also included are externally-
triggered microcapsules including the use of ultrasound and magnetic
flux triggering technologies, in situ activation inside microcapsules,
cell encapsulation, and urokinase and DNA measurement of metastasis for
diagnostic testing. The patent rights in these inventions have been
assigned to the United States of America as represented by the
Administrator of the National Aeronautics and Space Administration. The
prospective partially exclusive license will comply with the terms and
conditions of 35 U.S.C. 209 and 37 CFR 404.7.
DATES: The prospective partially exclusive license may be granted
unless, within fifteen (15) days from the date of this published
notice, NASA receives written objections including evidence and
argument that establish that the grant of the license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Competing applications completed and received by NASA within fifteen
(15) days of the date of this published notice will also be treated as
objections to the grant of the contemplated exclusive license.
Objections submitted in response to this notice will not be made
available to the public for inspection and, to the extent permitted by
law, will not be released under the Freedom of Information Act, 5
U.S.C. 552.
ADDRESSES: Objections relating to the prospective license may be
submitted to Patent Counsel, Office of Chief Counsel, Mail Code AL,
2101 NASA Parkway, Houston, TX 77058, (281) 483-4871; (281) 483-6936
[Facsimile].
FOR FURTHER INFORMATION CONTACT: Theodore U. Ro, Patent Attorney,
Office of Chief Counsel, Johnson Space Center, Mail Code AL, 2101 NASA
Parkway, Houston, TX 77058, (281)244-7148; (281)483-6936 [Facsimile].
Information about other NASA inventions available for licensing can be
found online at https://technology.nasa.gov/.
Dated: August 7, 2009.
Richard W. Sherman,
Deputy General Counsel.
[FR Doc. E9-19487 Filed 8-14-09; 8:45 am]
BILLING CODE P
